Tensha Therapeutics is developing small molecule bromodomain inhibitors, a new class of epigenetic modulators of gene expression, to treat cancer and other serious disorders.

The company's programs are based on the discovery of potent small molecule BET bromodomain inhibitors from the laboratory of Dr. James Bradner at Harvard Medical School and the Dana-Farber Cancer Institute. Tensha’s lead compound, TEN-010, is currently in early clinical development for the treatment of patients with solid tumors, including NUT midline carcinoma (NMC). Tensha is a Focused Portfolio Company funded by HealthCare Ventures.

News & Publications

  • Tensha Therapeutics Announces First Clinical Trial of BET Bromodomain Inhibitor TEN-010 for Treatment of Cancer
    Download PDF of Press Release »
  • Tensha Therapeutics Completes $15 Million Series A Financing
    Download PDF of Press Release »
  • Efficacy of BET bromodomain inhibition in Kras-mutant non-small lung cancer
    Clinical Cancer Research Sep 2013
    Go »
  • MYC, a downstream target of BRD-NUT, is necessary and sufficient for the blockade of differentiation in NUT midline carcinoma
    Oncogene April 2013
    Go »
  • Selective inhibition of tumor oncogenes by disruption of super-enhancers
    Cell April 2013
    Go »
  • Targeting MYCN in neuroblastoma by BET bromodomain inhibition
    Cancer Discovery March 2013
    Go »